India & Lupin (company)

India: India is the largest supplier of generic drugs to the US; the tariffs threaten its $9.7 billion pharma export market and could force strategic shifts.

Lupin (company): Lupin is a major generic drug supplier to the US; the tariff plan poses a risk to its US market share.

India: India becomes the seventh country to launch Awiqli, addressing its high diabetes burden and potentially improving public health outcomes.

Lupin (company): Lupin's insulin glargine products face increased competition from Awiqli.

India: India is the home country of Lupin (company) and is represented by 16 companies, including Lupin (company), on the global sustainability ranking.

Lupin (company): Lupin (company) was recognized as one of the World's Most Sustainable Companies by TIME and Statista, highlighting its strong ESG performance and commitment to sustainability.

India: The manufacturing site in Pithampur, India, is the source of the recalled product, potentially affecting India's pharmaceutical export reputation.

Lupin (company): Lupin (company) is the manufacturer of the recalled eye drops; the recall may harm its brand and lead to potential liability, though the company is cooperating voluntarily.

India: Lupin (company) and Natco Pharma, both headquartered in India, have expanded their global reach through this U.S. FDA approval.

Lupin (company): Lupin (company), in partnership with Natco Pharma, received U.S. FDA approval for Eribulin Mesylate Injection, which is expected to provide a competitive edge in the oncology market and contribute to its sales.

India: India is a key market for Vitabiotics via Meyer Organics, and Bain Capital's Asia team will drive growth there.

Lupin (company): Lupin was in early-stage discussions to acquire Vitabiotics but did not proceed.

India: Lupin is headquartered in India, and the spin-out reflects its global strategy.

Lupin (company): Lupin spins out two oncology assets to Kaveri, retaining significant equity and providing seed funding, which may streamline its pipeline and create value.

Lupin (company): Lupin (company) is preparing to roll out generic semaglutide and has formed a licensing partnership with Astec LifeSciences, aiming to compete in the Indian weight-loss drug market.

Lupin (company): Lupin (company) entered a licensing and supply agreement with Astec LifeSciences to co-market Semaglutide Injection in India, gaining semi-exclusive rights to distribute the drug under its own brand names. This enhances its diabetes portfolio and strengthens its commitment to advanced cardio-metabolic treatments.